澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; silicon dioxide; hypromellose; carnauba wax; lactose monohydrate; croscarmellose sodium; titanium dioxide; macrogol 3000 - karvea is indicated for the treatment of hypertension. karvea is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (more than or equal to 30 mg per 24 hour) or urinary protein in excess of 900 mg per 24 hours

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - irbesartan, quantity: 150 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000 - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; macrogol 6000; magnesium stearate; sodium starch glycollate type b; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type b; lactose monohydrate; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; macrogol 6000; magnesium stearate; polysorbate 80 - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; colloidal anhydrous silica; mannitol; polysorbate 80; sodium starch glycollate type b; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; carnauba wax; macrogol 3350 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; macrogol 6000; hyprolose; magnesium stearate; colloidal anhydrous silica - noumed irbesartan/hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; sodium stearylfumarate; hyprolose; purified talc; titanium dioxide; polyvinyl alcohol; macrogol 3350 - irbesartan tih is indicated for the treatment of hypertension. irbesartan tih is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; sodium stearylfumarate; hyprolose; purified talc; titanium dioxide; polyvinyl alcohol; macrogol 3350 - irbesartan spr is indicated for the treatment of hypertension. irbesartan spr is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

美国 - 英文 - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide is indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy

美国 - 英文 - NLM (National Library of Medicine)

hisun pharmaceuticals usa inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets usp may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets usp may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets usp as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving